- Report
- February 2024
- 152 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2023
- 205 Pages
North America
From €3022EUR$3,450USD£2,623GBP
- Report
- February 2023
- 192 Pages
Asia Pacific
From €3022EUR$3,450USD£2,623GBP
- Report
- February 2023
- 205 Pages
Africa, Middle East
From €3022EUR$3,450USD£2,623GBP
- Report
- December 2022
- 267 Pages
Global
From €3897EUR$4,450USD£3,383GBP
- Report
- February 2025
- 84 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- August 2023
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- August 2024
- 142 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- December 2024
- 150 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- October 2024
- 99 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- November 2025
- 132 Pages
Global
From €832EUR$950USD£722GBP
- Report
- July 2024
- 132 Pages
Global
From €832EUR$950USD£722GBP

The Sepsis Test market is a subset of the Diagnostics industry, focused on the detection and diagnosis of sepsis. Sepsis is a life-threatening condition caused by the body's response to an infection, and early diagnosis is critical for successful treatment. Sepsis tests are used to detect the presence of sepsis-causing bacteria in the blood, and to identify the type of bacteria present. Tests may also be used to monitor the progress of treatment.
Sepsis tests are typically performed in a laboratory setting, and may include blood cultures, urine cultures, and other tests. Tests may also be performed using point-of-care devices, which allow for rapid diagnosis in the clinical setting.
Companies in the Sepsis Test market include Abbott, Becton Dickinson, bioMérieux, Cepheid, DiaSorin, and Roche. Show Less Read more